

# Louise Downey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/451817/publications.pdf>

Version: 2024-02-01

7  
papers

261  
citations

1307594

7  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

386  
citing authors

#	ARTICLE	IF	CITATIONS
1	The changing landscape for the management of patients with neovascular AMD: brolocizumab in clinical practice. <i>Eye</i> , 2022, 36, 1725-1734.	2.1	14
2	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	2.1	104
3	&lt;p&gt;Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 1315-1328.	1.8	11
4	Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1731-1740.	1.8	19
5	UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. <i>British Journal of Ophthalmology</i> , 2017, 101, 1683-1688.	3.9	37
6	Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA. <i>Ophthalmology and Therapy</i> , 2017, 6, 175-186.	2.3	18
7	UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. <i>British Journal of Ophthalmology</i> , 2015, 99, 1045-1050.	3.9	51